Baird Raises Biogen Price Target to $290 From $250
Baird maintained its Outperform rating and raised its price target from $250 to $290, a 16.0% increase. The new target implies 18.8% upside from the Oct. 28 close of $244.05.
Related stories
Sanwa Holdings to Buy Back Up to 1.8% of Shares
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Vedanta Power Swings to Rs 83 Crore Q2 Profit as Revenue Climbs 38%
Revenue rose 38% year on year to Rs 2,908 crore, and net debt declined to Rs 7,444 crore.
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Coal India Q2 Profit Rises 53% as Revenue Reaches Rs 44,178.74 Crore
Revenue from operations rose to Rs 44,178.74 crore year on year. The board approved a second interim dividend of Rs 10.25 per share.
M impact | EQUITY | Oct 30, 2026, 02:32 AM UTC
Daewoo Engineering & Construction Wins Won 330.3 Billion Order
Daewoo Engineering & Construction won an order worth 330.3 billion won.
M impact | EQUITY | Oct 30, 2026, 02:31 AM UTC
Daito Trust reports interim profit up 28.6%, forecasts annual profit up 10.1%
Daito Trust reported consolidated interim profit of 641.75億円, up 28.6%, and forecast profit of 1090.00億円 for the fiscal year ending March, up 10.1%.
M impact | EQUITY | Oct 30, 2026, 02:31 AM UTC
Asian session market picture: S&P 500 -1.04%, Nasdaq 100 -2.25%; USD/JPY -0.12%, WTI +1.81%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 1.04 percent, Nasdaq futures is down 2.25 percent, Dow futures is down 0.26 percent and Russell futures is d
M impact | EQUITY | Oct 30, 2026, 02:30 AM UTC